What is resistant arterial hypertension?

References

• Acelajado MC, Hughes ZH, Oparil S, et al. Treatment of resistant and refractory hypertension. Circ Res. 2019;124(7):1061–1070.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2017;71(6):1269–1324.
   PubMed Web of Science ®Google Scholar
• Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement From the American heart association. Hypertension. 2018;72(5):E53–E90.
   PubMed Web of Science ®Google Scholar
• Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American heart association cou. Circulation. 2005;111(5):697–716.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research. Hypertension. 2008;51(6):1403–1419.
   PubMed Web of Science ®Google Scholar
• Parati G, Stergiou GS, Asmar R, et al. European society of hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779–785.
   PubMed Web of Science ®Google Scholar
• Bhatt H, Siddiqui M, Judd E, et al. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016;10(6):493–499.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Ventura HO, Amodeo C. Osler’s maneuver and pseudohypertension. N Engl J Med. 1985;312(24):1548–1551.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical pr. J Am Coll Cardiol. 2018;71(19):e127–e248.
   PubMed Web of Science ®Google Scholar
• Mancia G, Facchetti R, Vanoli J, et al. White-coat hypertension without organ damage: impact on long-term mortality, new hypertension, and new organ damage. Hypertension. 2022;79(5):1057–1066.
   PubMed Web of Science ®Google Scholar
• Grassi G, Turri C, Vailati S, et al. Muscle and skin sympathetic nerve traffic during the ‘white-coat’ effect. Circulation. 1999;100(3):222–225.
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med. 2008;168(21):2340–2346.
   PubMedGoogle Scholar
• de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902.
   PubMed Web of Science ®Google Scholar
• Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30(2):83–89.
   PubMed Web of Science ®Google Scholar
• Schulz M, Krueger K, Schuessel K, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668–676.
   PubMed Web of Science ®Google Scholar
• Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10(Suppl 1):20–26.
   PubMed Web of Science ®Google Scholar
• Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011.
   PubMedGoogle Scholar
• Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29(4):213–218.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719.
   PubMed Web of Science ®Google Scholar
• Kassavou A, Wang M, Mirzaei V, et al. The association between smartphone app-based self-monitoring of hypertension-related behaviors and reductions in high blood pressure: systematic review and meta-analysis. JMIR mHealth uHealth. 2022;10(7):e34767.
   PubMed Web of Science ®Google Scholar
• Borghi C, Tubach F, De Backer G, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study. Int J Cardiol. 2016;218:83–88.
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with reviewer disclosures reviewer employment research grant other research support speakers’ Bureau/Honoraria Exp – Search Results – PubMed; 2022. https://pubmed.ncbi.nlm.nih.gov/?term=longqueryec1bd4807d9e18d38fb3
   Google Scholar
• Thomas G, Xie D, Chen H-Y, CRIC Study Investigators, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report From the chronic renal insufficiency cohort study. Hypertension. 2016;67(2):387–396.
   PubMed Web of Science ®Google Scholar
• Shalaeva E, Bano A, Kasimov U, et al. Coronary artery calcium score and coronary computed tomography angiography predict one-year mortality in patients with type 2 diabetes and peripheral artery disease undergoing partial foot amputation. Diabetes Vasc. Dis. Res. 2022;19(5):147916412211251.
   Web of Science ®Google Scholar
• Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691–697.
   PubMed Web of Science ®Google Scholar
• Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583–1590.
   PubMed Web of Science ®Google Scholar
• Smith SM, Huo T, Delia Johnson B, et al. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE study. J Am Heart Assoc. 2014;3(1):e000660.
   Web of Science ®Google Scholar
• Sim JJ, Bhandari SK, Shi J, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099–1107.
   PubMed Web of Science ®Google Scholar
• Osborn JW, Banek CT. Catheter-based renal nerve ablation as a novel hypertension therapy: lost, and then found, in translation. Hypertension. 2018;71(3):383–388.
   PubMed Web of Science ®Google Scholar
• Appel LJ, American Society of Hypertension Writing Group; Giles TD, et al. ASH position paper: dietary approaches to lower blood pressure. J Clin Hypertens (Greenwich). 2009;11(7):358–368.
   PubMed Web of Science ®Google Scholar
• Saneei P, Salehi-Abargouei A, Esmaillzadeh A, et al. Influence of dietary approaches to stop hypertension (DASH) diet on blood pressure: a systematic review and meta-analysis on randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24(12):1253–1261.
   PubMed Web of Science ®Google Scholar
• Shimbo D, Levitan EB, Booth JN, et al. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the reasons for geographic And racial differences in stroke (REGARDS) study. J Hypertens. 2013;31(2):370–376.
   PubMed Web of Science ®Google Scholar
• Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone compliance to high blood pressure therapy scale. Prog Cardiovasc Nurs. 2000;15(3):90–96.
   PubMedGoogle Scholar
• Coppolino G, Pisano A, Rivoli L, et al. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2017;2(2):CD011499.
   PubMedGoogle Scholar
• Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American heart association sodium reduction recommendations. Circulation. 2012;126(24):2880–2889.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bavishi C, Brguljan J, et al. Renal denervation in the antihypertensive arsenal – knowns and known unknowns. J Hypertens. 2022;40(10):1859–1875.
   PubMed Web of Science ®Google Scholar
• Blaustein MP, Leenen FHH, Chen L, et al. How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension. Am J Physiol Heart Circ Physiol. 2012;302(5):H1031–1049.
   Web of Science ®Google Scholar
• Sidikov A, Zaslavsky D, Sadykov A, et al. The new differential diagnostic test for the lichenoid drug eruption. Dermatol Ther. 2020;33(6):e13784.
   Web of Science ®Google Scholar
• Oh YS, Appel LJ, Galis ZS, et al. National heart, lung, and blood institute working group report on salt in human health and sickness: building on the current scientific evidence. Hypertension. 2016;68(2):281–288.
   PubMed Web of Science ®Google Scholar
• Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475–481.
   PubMed Web of Science ®Google Scholar
• McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24(12):2096–2103.
   PubMed Web of Science ®Google Scholar
• Diaz KM, Shimbo D. Physical activity and the prevention of hypertension. Curr Hypertens Rep. 2013;15(6):659–668.
   PubMed Web of Science ®Google Scholar
• Carnethon MR, Evans NS, Church TS, et al. Joint associations of physical activity and aerobic fitness on the development of incident hypertension: coronary artery risk development in young adults. Hypertension. 2010;56(1):49–55.
   PubMed Web of Science ®Google Scholar
• Chase NL, Sui X, Lee DC, et al. The association of cardiorespiratory fitness and physical activity with incidence of hypertension in men. Am J Hypertens. 2009;22(4):417–424.
   PubMed Web of Science ®Google Scholar
• Crump C, Sundquist J, Winkleby MA, et al. Interactive effects of physical fitness and body mass index on the risk of hypertension. JAMA Intern Med. 2016;176(2):210–216.
   PubMed Web of Science ®Google Scholar
• Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. JAMA. 2009;302(4):401–411.
   PubMed Web of Science ®Google Scholar
• Dimeo F, Pagonas N, Seibert F, et al. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012;60(3):653–658.
   PubMed Web of Science ®Google Scholar
• McFadden CB, Brensinger CM, Berlin JA, et al. Systematic review of the effect of daily alcohol intake on blood pressure. Am J Hypertens. 2005;18(2 Pt 1):276–286.
   PubMed Web of Science ®Google Scholar
• Chen L, Smith GD, Harbord RM, et al. Alcohol intake and blood pressure: a systematic review implementing a mendelian randomization approach. PLoS Med. 2008;5(3):0461–0471.
   Web of Science ®Google Scholar
• Briasoulis A, Agarwal V, Messerli FH. Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2012;14(11):792–798.
   PubMed Web of Science ®Google Scholar
• Husain K, Ansari RA, Ferder L. Alcohol-induced hypertension: mechanism and prevention. World J Cardiol. 2014;6(5):245–252.
   PubMedGoogle Scholar
• Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–335.
   PubMed Web of Science ®Google Scholar
• Lim LF, Solmi M, Cortese S. Association between anxiety and hypertension in adults: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;131:96–119.
   PubMed Web of Science ®Google Scholar
• Johnson HM. Anxiety and hypertension: is there a link? A literature review of the comorbidity relationship Between anxiety and hypertension. Curr Hypertens Rep. 2019;21(9):1–7.
   Web of Science ®Google Scholar
• Nemcsik-Bencze Z, et al. Depression and anxiety in different hypertension phenotypes: a cross-sectional study. Ann Gen Psychiatry. 2022;21(1):23.
   PubMed Web of Science ®Google Scholar
• Narita K, Hoshide S, Tsoi K, et al. Disaster hypertension and cardiovascular events in disaster and COVID‐19 pandemic. J Clin Hypertens (Greenwich). 2021;23(3):575–583.
   PubMed Web of Science ®Google Scholar
• Shimokawa H, et al. Guidelines for disaster medicine for patients with cardiovascular diseases (JCS 2014/JSH 2014/JCC 2014) – digest version. Circ. J. 2016;80(1):261–284.
   PubMed Web of Science ®Google Scholar
• Haas SA, Ramirez D. Childhood exposure to war and adult onset of cardiometabolic disorders among older europeans. Soc Sci Med. 2022;309:115274.
   PubMed Web of Science ®Google Scholar
• Acharya T, Tringali S, Singh M, et al. Resistant hypertension and associated comorbidities in a veterans affairs population. J Clin Hypertens (Greenwich). 2014;16(10):741–745.
   PubMed Web of Science ®Google Scholar
• Bakhtar O, Ference BA, Hedquist LA, et al. Relationship of resistant hypertension and treatment outcomes with total arterial compliance in a predominantly african American hypertensive cohort. J Clin Hypertens (Greenwich). 2012;14(9):618–622.
   PubMed Web of Science ®Google Scholar
• Holecki M, Duława J, Chudek J. Resistant hypertension in visceral obesity. Eur J Intern Med. 2012;23(7):643–648.
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19(11):2063–2070.
   PubMed Web of Science ®Google Scholar
• Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076–1080.
   PubMed Web of Science ®Google Scholar
• de La Sierra A, Larrousse M, Oliveras A, et al. Abnormalities of vascular function in resistant hypertension. Blood Press. 2012;21(2):104–109.
   PubMed Web of Science ®Google Scholar
• Shalaeva EV, Shadmanov AК, Azizova FL, et al. Is lone hypertension a risk factor for more severe COVID-19 outcomes? Glob Heart. 2022;17(1):17.
   PubMed Web of Science ®Google Scholar
• Oliveras A, De La Sierra A. Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens. 2014;28(4):213–217.
   PubMed Web of Science ®Google Scholar
• Demede M, Pandey A, Zizi F, et al. Resistant hypertension and obstructive sleep apnea in the primary-care setting. Int J Hypertens. 2011;2011:340929.
   PubMedGoogle Scholar
• Muxfeldt ES, Cardoso CRL, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169(9):874–880.
   PubMedGoogle Scholar
• Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811–817.
   PubMed Web of Science ®Google Scholar
• Pimenta E, Stowasser M, Gordon RD, et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013;143(4):978–983.
   PubMed Web of Science ®Google Scholar
• Friedman O, Bradley TD, Ruttanaumpawan P, et al. Independent association of drug-resistant hypertension to reduced sleep duration and efficiency. Am J Hypertens. 2010;23(2):174–179.
   PubMed Web of Science ®Google Scholar
• Quinaglia T, Martins LC, Figueiredo VN, et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011;25(11):656–664.
   PubMed Web of Science ®Google Scholar
• Salles GF, Ribeiro FM, Guimarães GM, et al. A reduced heart rate variability is independently associated with a blunted nocturnal blood pressure fall in patients with resistant hypertension. J Hypertens. 2014;32(3):644–651.
   PubMed Web of Science ®Google Scholar
• Kansui Y, Matsumura K, Kida H, et al. Clinical characteristics of resistant hypertension evaluated by ambulatory blood pressure monitoring. Clin Exp Hypertens. 2014;36(7):454–458.
   PubMed Web of Science ®Google Scholar
• Gonzaga CC, Gaddam KK, Ahmed MI, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363.
   PubMed Web of Science ®Google Scholar
• Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217–2226.
   PubMed Web of Science ®Google Scholar
• Hottenga J-J, Boomsma DI, Kupper N, et al. Heritability and stability of resting blood pressure. Twin Res Hum Genet. 2005;8(5):499–508.
   PubMed Web of Science ®Google Scholar
• Snieder H, Harshfield GA, Treiber FA. Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension. 2003;41(6):1196–1201.
   PubMed Web of Science ®Google Scholar
• Kupper N, Willemsen G, Riese H, et al. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension. 2005;45(1):80–85.
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Johnson T, Gateva V, Wellcome Trust Case Control Consortium, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41(6):666–676.
   PubMed Web of Science ®Google Scholar
• Yugar-Toledo JC, Martin JFV, Krieger JE, et al. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011;30(8):555–564.
   PubMed Web of Science ®Google Scholar
• Oliveira-Paula GH, Lacchini R, Coeli-Lacchini FB, et al. Inducible nitric oxide synthase haplotype associated with hypertension and responsiveness to antihypertensive drug therapy. Gene. 2013;515(2):391–395.
   PubMed Web of Science ®Google Scholar
• Lynch AI, Irvin MR, Davis BR, et al. Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT. Int. J. Hypertens. 2013;2013:1–10.
   Google Scholar
• Fontana V, McDonough CW, Gong Y, et al. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. JAHA. 2014;3(6):e001398.
   Google Scholar
• Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–353.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–1642.
   PubMed Web of Science ®Google Scholar
• Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622–632.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Shalaeva EV, Rexhaj E. Optimal BP targets to prevent stroke and MI: is there a lesser of 2 evils? J Am Coll Cardiol. 2021;78(17):1679–1681.
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Kasiakogias A, Kordalis A, et al. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014;32(2):415–422.
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):1422–1428.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014;127(1):71–81.e1.
   PubMed Web of Science ®Google Scholar
• Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635–643.
   PubMed Web of Science ®Google Scholar
• Jin C-N, Liu M, Sun J-P, et al. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS One. 2014;9(12):e114958.
   PubMed Web of Science ®Google Scholar
• Freeman MW, Halvorsen Y-D, Marshall W, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395–405.
   PubMed Web of Science ®Google Scholar
• Bogman K, Schwab D, Delporte M-L, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69(1):189–196.
   PubMed Web of Science ®Google Scholar